Author Manuscript Published OnlineFirst on May 6, 2011; DOI: 10.1158/1535-7163.MCT-10-1028 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues (PIAs) in NSCLC cells Chunyu Zhang1, Abdel G. Elkahloun2, Hongling Liao3, Shannon Delaney1, Barbara Saber1, Betsy Morrow1, Joell J. Gills1, M. Christine Hollander1, George C. Prendergast4 and Phillip A. Dennis1* 1Medical Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD 20892 2Cancer Genetics Branch, NHGRI, NIH, Bethesda, MD 20892 3Sequencing Facility, SAIC-Frederick, NCI at Frederick, Gaithersburg, MD 20877 4Lankenau Institute for Medical Research, Wynnewood, PA 19096 Running Title: Expression profiling of PIAs Keywords: Akt, microarray, PIA, RhoB, NSCLC Abbreviations: PI3K, phosphatidylinositol 3’ kinase; NSCLC, non-small cell lung cancer; PIA, phosphatidylinositol ether lipid analogue; LY, LY294002; MAPK, mitogen-activated protein kinase This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract NCI Contract NO1-CO-12400. *To whom correspondence should be addressed- 37 Convent Dr., Rm. 1118B, Bethesda, MD 20892, USA Phone: (301)-496-0929. Fax: (301)-435-4345. E-mail:
[email protected] The authors have no conflict of interest. The manuscript has 4809 words (excluding references), 4 figures and 2 tables. 1 Downloaded from mct.aacrjournals.org on September 29, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 6, 2011; DOI: 10.1158/1535-7163.MCT-10-1028 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.